BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Public ClinicalTrials.gov record NCT05156710. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.
Study identification
- NCT ID
- NCT05156710
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- Antithymocyte globulin (ATG) Drug
- BIVV020 (SAR445088) Drug
- Corticosteroids Drug
- Intravenous immunoglobulin (IVIg) Drug
- Mycophenolate Drug
- Rituximab or biosimilar Drug
- Tacrolimus Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2022
- Primary completion
- Oct 20, 2025
- Completion
- Oct 25, 2026
- Last update posted
- Feb 23, 2026
2022 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center- Site Number : 8400100 | Los Angeles | California | 90048 | — |
| University of California Los Angeles Medical Center- Site Number : 8400103 | Los Angeles | California | 90095 | — |
| University of California San Francisco - Parnassus Heights- Site Number : 8400001 | San Francisco | California | 94143 | — |
| Massachusetts General Hospital- Site Number : 8400007 | Boston | Massachusetts | 02114 | — |
| Brigham & Women's Hospital- Site Number : 8400004 | Boston | Massachusetts | 02115 | — |
| NYU Langone Medical Center- Site Number : 8400102 | New York | New York | 10016 | — |
| University of Wisconsin Hospitals and Clinics- Site Number : 8400003 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05156710, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05156710 live on ClinicalTrials.gov.